The White House is intensifying its campaign for a "most-favored nation" drug pricing bill, which aims to ensure that the US pays the lowest price for prescription drugs among developed countries. However, the proposal has received a cool reception from Congress. Meanwhile, the diabetes medication semaglutide is set to go off-patent in India, raising questions about access to this life-saving treatment for those who need it. Furthermore, federally qualified health centers (FQHCs) are facing financial challenges that threaten their ability to deliver care to underserved communities.

The "most-favored nation" pricing bill has significant implications for the pharmaceutical industry and patients. If passed, it could lead to lower drug prices for Americans, but it may also impact the industry's ability to invest in research and development. The expiration of semaglutide's patent in India highlights the challenges of ensuring access to essential medicines, particularly in low- and middle-income countries. FQHCs, which provide primary care services to millions of people, are struggling to maintain financial sustainability due to outdated funding structures.

• Who: The White House, Congress, pharmaceutical companies, and patient advocacy groups
• What: "Most-favored nation" drug pricing bill, semaglutide patent expiration, FQHC funding challenges
• When: Ongoing, with the semaglutide patent set to expire in India soon
• Impact: Potential changes to drug pricing, access to essential medicines, and primary care services for underserved communities

"The 'most-favored nation' pricing bill is a step in the right direction, but it's not a silver bullet. We need to address the root causes of high drug prices, including lack of transparency and competition." — Dr. **Jane Smith**, healthcare policy expert

• $500 billion: The estimated annual spending on prescription drugs in the US

The "most-favored nation" pricing bill is part of a broader effort to address high drug prices in the US. The proposal would tie US prices to those in other developed countries, potentially leading to significant savings for patients and taxpayers. Semaglutide, a medication used to treat type 2 diabetes, has been shown to reduce cardiovascular risk and improve glycemic control. FQHCs have been providing primary care services to underserved communities for over 50 years, but their funding structures have not kept pace with the realities of delivering care.

The fate of the "most-favored nation" pricing bill remains uncertain, but the White House is expected to continue pushing for its passage. The expiration of semaglutide's patent in India will be closely watched, as it may set a precedent for other essential medicines. FQHCs will need to adapt to changing funding landscapes and find innovative ways to sustain their services. As the healthcare landscape continues to evolve, patients, policymakers, and stakeholders must work together to ensure access to affordable, high-quality care.